News

The data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), held March 5-7, 2010 in San Francisco, CA. TAK-700, discovered by Takeda,

The companies have earmarked an estimated total of $1.4bn for the expansion. They have begun the expansion at BYC in September 2009. According to Johnny Kwan, board chairman

Archexin is a potent inhibitor of Akt protein kinase in the treatment of cancer. Akt regulates signal processes of cell proliferation and survival, angiogenesis, and drug resistance in

Stentys said that the self-expanding feature of the platform is designed to ensure optimal apposition of a stent in the critical initial hours and days after an acute

The company has reported a net loss of $1,433,922, or ($0.11) per share, compared with a net loss of $11,852,152, or ($1.12) per share. Opexa has posted an

SecureTrace is a syndicate of 10 companies in the UK that are using technology to fight counterfeiting and diversion of pharmaceuticals throughout the supply chain. The project, according

Taro said that its fluorouracil cream is a prescription pharmaceutical product used for topical treatment of multiple actinic or solar keratoses and superficial basal cell carcinomas, and is

NerPharMa manufactures CTI’s drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product. CTI has a New Drug Application (NDA)

For over four years, Post-Op Px has integrated tissue, clinical and molecular information to enable physicians and their patients to make more informed decisions about post-surgical, adjuvant therapies.